Abstract
Sepsis is a complex clinical situation responsible for thousands of deaths annually in intensive care units around the globe. Despite all our progress in providing medical care to critically ill patients, mortality of severe forms of sepsis did not decrease as expected. Part of this phenomenon is due to our defective understanding about the host immune response to aggression by a microorganism, including the part played by the pattern-recognition receptors (PRRs) in this process. PRRs are part of the innate immunity responsible for detecting non-self antigens and trigger the initial inflammatory response. The best known PRRs are the tol-like receptors (TLRs). In this article, we review some of our knowledge regarding the role of TLRs in sepsis, both in experimental models and in human patients. The improvement in our knowledge about the mediators and signaling pathways that control this immune response is crucial for the development of better markers of disease and new therapeutic targets, leading us to improve the way we treat septic patients.
Keywords: Pattern recognition receptors, sepsis, toll-like receptors
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Toll-Like Receptors in Sepsis: A Tale Still Being Told
Volume: 10 Issue: 3
Author(s): Heraldo Possolo Souza, Thais Lima-Salgado and Luis Monteiro da Cruz Neto
Affiliation:
Keywords: Pattern recognition receptors, sepsis, toll-like receptors
Abstract: Sepsis is a complex clinical situation responsible for thousands of deaths annually in intensive care units around the globe. Despite all our progress in providing medical care to critically ill patients, mortality of severe forms of sepsis did not decrease as expected. Part of this phenomenon is due to our defective understanding about the host immune response to aggression by a microorganism, including the part played by the pattern-recognition receptors (PRRs) in this process. PRRs are part of the innate immunity responsible for detecting non-self antigens and trigger the initial inflammatory response. The best known PRRs are the tol-like receptors (TLRs). In this article, we review some of our knowledge regarding the role of TLRs in sepsis, both in experimental models and in human patients. The improvement in our knowledge about the mediators and signaling pathways that control this immune response is crucial for the development of better markers of disease and new therapeutic targets, leading us to improve the way we treat septic patients.
Export Options
About this article
Cite this article as:
Possolo Souza Heraldo, Lima-Salgado Thais and Monteiro da Cruz Neto Luis, Toll-Like Receptors in Sepsis: A Tale Still Being Told, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936919
DOI https://dx.doi.org/10.2174/187153010791936919 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Sol-gel Derived Warfarin – Silica Composites for Controlled Drug Release
Current Drug Delivery In vivo MRS of Muscle, Liver, Heart and Other Organs: A Review of Techniques and Applications
Current Molecular Imaging (Discontinued) New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Administration of a Synbiotic to Free-Living Elderly and Evaluation of Serum Cytokines. A Pilot Study
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Cellular Uptake and Organ Accumulation of Amphipolar Metallocorroles with Cytoprotective and Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Collagenolytic Enzymes and their Applications in Biomedicine
Current Medicinal Chemistry Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
Vascular Disease Prevention (Discontinued) Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design